CorMedix Inc. (CRMD)
- Previous Close
9.03 - Open
9.59 - Bid 8.10 x 200
- Ask 12.28 x 200
- Day's Range
9.49 - 11.40 - 52 Week Range
3.61 - 13.85 - Volume
4,183,423 - Avg. Volume
1,529,943 - Market Cap (intraday)
756.765M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.30 - Earnings Date May 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.50
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
www.cormedix.comRecent News: CRMD
View More
Performance Overview: CRMD
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRMD
View MoreValuation Measures
Market Cap
756.76M
Enterprise Value
705.59M
Trailing P/E
--
Forward P/E
15.95
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.11
Price/Book (mrq)
8.94
Enterprise Value/Revenue
16.23
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.24%
Return on Assets (ttm)
-13.91%
Return on Equity (ttm)
-23.17%
Revenue (ttm)
43.47M
Net Income Avi to Common (ttm)
-17.93M
Diluted EPS (ttm)
-0.30
Balance Sheet and Cash Flow
Total Cash (mrq)
51.69M
Total Debt/Equity (mrq)
0.61%
Levered Free Cash Flow (ttm)
-44.72M